Horizon Pharma plc Provides Comment on Express Scripts' Business Practices
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Horizon Pharma plc Provides Comment on Express Scripts' Business Practices
November 12, 2015 9:14 AM EST
UBS analyst Marc Goodman, published a note on Horizon Pharma (NASDAQ: HZNP) in the wake of negative press:
Express Scripts (NASDAQ: ESRX) is suing Horizon for $140M of owed rebates under a contractual agreement that Horizon... More
November 11, 2015 12:12 PM EST
(NOTE - The following follows an earlier statement made by Horizon.)
Horizon Pharma plc (Nasdaq: HZNP) commented on Express Scripts' (Nasdaq: ESRX) business practices.
"Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for... More
November 11, 2015 11:57 AM EST
Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they expect minimal impact from Linden disruption.
Koffler commented, "We spoke with management and learned that Linden processes ~150-200 prescriptions for Duexis, Vimovo, Pennsaid, and... More
